British healthtech company Huma Therapeutics has partnered with Eckuity Capital to lay the foundations for an “aggressive” new M&A strategy.
Huma develops AI-based tools for healthcare data integrations, patient wearables and other mobile devices to securely transmit data for use by healthcare professionals (HCPs).
The company stated that its partnership with growth equity company Eckuity would support its development of technology infrastructure to support ongoing plans to acquire companies and launch digital solutions across the healthcare space.
Huma also stated that its strategy will involve the ongoing acquisition of “complementary” companies to build a “comprehensive digital ecosystem” that will support global health systems, CROs, and patients.
According to Eckuity Capital managing partner Youssef Sebban, its role will be in helping Huma to acquire companies that “may not fully realise” their potential on their own, yet become “highly complementary” when integrated into Huma’s cloud platform.
Along with the Eckuity partnership, Huma has acquired Aluna (formerly Knox Medical Diagnostics). According to Huma, integrating the US company’s respiratory monitoring offerings onto its platform will add 200 health systems and clinic chains to its existing 4,500 hospital network. Financial terms of the deal have not been publicly disclosed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHuma founder and CEO Dan Vahdat stated that its dual announcement marked a “new chapter” for the company as it aims to build the world’s “most impactful” healthcare company.
Vahdat said: “By integrating Aluna’s leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and most importantly, patients around the world.”
Aluna CEO Charvi Shetti said: “Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide.”
Huma received Class II clearance from the US Food and Drug Administration (FDA) for its platform as a software as a medical device (SaMD) in 2023, making it one of the first successful applicants to the FDA’s eSTAR programme, in partnership with Health Canada.
